The model’s accurate estimation of disease stages underscores the value of DEBM for patient stratification, offer a promising tool to support clinical trial design and provide a temporal ordering of multiple CSF proteins.
J. D. De Houwer, Wenjie Kang, Renee van Buuren et al.· Alzheimer's Research & T...· 0 citations
Machine-learning stratification of genetic FTD reveals a progressive and a dissociated disease track and provides individualized progression scores that closely track clinical status, enabling smaller, more efficient prevention and early-intervention trials than conventional MRI or NfL markers alone.
M. Soltaninejad, Y. Iturria-Medina, A. Bouzigues et al.· bioRxiv· 0 citations
It is concluded that rare coding CNVs in a proportion of AD-associated genes and 22q11.21 duplication as a strong AD-risk-decreasing factor increase AD risk and Conversely, 22q11.21 duplication as a strong AD-risk-decreasing factor is identified.
O. Quenez, Catherine Schramm, K. Cassinari et al.· American Journal of Human Ge...· 1 citation
Sex and educational attainment significantly affect the development and maintenance of cognitive reserve in individuals with genetic FTD, and underscore the importance of identifying disease-modifying interventions since the presymptomatic stages of the disease.
E. Premi, Damiano Archetti, A. Redolfi et al.· Brain Communications· 0 citations
Frontotemporal lobar degeneration (FTLD) is a common cause of early-onset dementias marked by progressive declines in behavior, cognition, and/or movement. FTLD neuropathologies, including TDP-43 proteinopathies and primary tauopathies, do not have reliable fluid biomarkers for in-vivo diagnosis nor biomarkers that dir...
H. Oh, J. Downer, Connor D. Dietz et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
